Purpose: This analysis from Avastin® Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) and postprogression survival (PPS) in bevacizumab-exposed metastatic colorectal cancer (mCRC) through the application of time-dependent and time-fixed analytical methods.
Methods: Patients with mCRC who were treated with first-line bevacizumab and who survived first PD (PD1) were included. A time-dependent Cox regression model was fitted to assess the effect of cumulative bevacizumab exposure on PPS, while controlling for potential confounders. In addition to support findings from previous studies, a modified intent-to-treat (mITT) analysis compared PPS in patients who received bevacizumab beyond disease progression (BBP) with those who did not (No-BBP).
Results: Of 1550 patients, 1199 survived PD1 and had a median PPS of 13.4 months. Cumulative bevacizumab exposure was associated with improved PPS (p = 0.0040). After adjusting for confounders, the hazard ratios (HRs) for PPS decreased, on average, by 1.2% (range, 1.1-1.3%) with each additional dose of bevacizumab. In the mITT analysis, the median PPS for BBP (n = 438) was 14.4 months vs 10.6 months with for No-BBP (n = 667). BBP was found to be independently associated with longer PPS in a multivariable Cox regression analysis (HR, 0.84; 95% confidence interval, 0.73-0.97). Protocol-specified adverse events suspected to be associated with bevacizumab occurred in 13.0% of patients with BBP.
Conclusion: This analysis supports the observation that bevacizumab exposure after PD1 is associated with longer PPS in mCRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.3633 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.
Invest New Drugs
December 2024
Division of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy holds potential to induce synthetic lethality. This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
View Article and Find Full Text PDFEvaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.
Int J Clin Oncol
December 2024
Data Management Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Chuo-Ku, Japan.
Background: Febrile neutropenia (FN) is a recognised adverse event associated with chemotherapy. This study investigates the impact of atezolizumab, an immune checkpoint inhibitor, on the incidence of FN in patients with non-small cell lung cancer receiving concurrent chemotherapy in Japan.
Methods: This post-marketing database study was conducted using data from patients with non-small cell lung cancer provided by Medical Data Vision Co.
Risk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors.
Clin Transl Sci
December 2024
Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Whether or not vascular endothelial growth factor pathway inhibitors (VPIs) increase the risk of artery dissection is still unknown. This study aimed to quantitatively evaluate the possibility of artery dissection as a class effect of VPIs using nationwide real-world data. This cohort study was conducted based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which spans nearly the entire Japanese population of over 100 million individuals.
View Article and Find Full Text PDFExposure to Silicone Oil Endotamponades Induces VEGF Antibody Aggregation and Loss of Functionality.
Invest Ophthalmol Vis Sci
November 2024
The David J Apple Laboratory for Vision Research, Heidelberg, Germany.
Article Synopsis
- - The study examines how a monoclonal antibody (bevacizumab) interacts with silicone oils and hydrogels, revealing that exposure to silicone oils significantly decreases the antibody's functionality and causes aggregation.
- - Results show that after 24 hours in silicone oil, bevacizumab retains only 30% of its activity, leading to concerns about its clinical use during procedures that involve silicone oil tamponade.
- - Polysorbate, a common stabilizer, effectively reduces antibody aggregation, while hydrogels do not affect the functionality of the antibodies tested, making them a safer alternative for vitreous body replacement.
Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies.
JHEP Rep
November 2024
Cordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, F-75006 Paris, France.
Background & Aims: Safety data for patients with hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab in the real-world setting remain uncertain. Thus, the aim of this study was to evaluate the incidence of adverse events (AEs) in patients with HCC treated with atezolizumab-bevacizumab in the literature.
Methods: In this systematic review and meta-analysis, we searched PubMed for original studies reporting percentages of AEs in patients with HCC receiving atezolizumab-bevacizumab between 2020 to 2023, using the search terms "Atezolizumab/Bevacizumab", "HCC" and "Adverse events".
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!